Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
[space][space][space][space][space]2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Treatment Type
6.1 Chemotherapy
6.2 Surgery
6.3 Radiation Therapy
6.4 Immunotherapy
6.5 Targeted Therapy
6.6 Signal Transduction Inhibitors
6.7 Stem Cell Transplant
6.8 Hormonal Therapy
6.9 Apoptosis Inducers
6.10 Others
Chapter 7 Market Segmentation by Cancer Type
7.1 Eye Cancer
7.2 Bone Cancer
7.3 Brain Cancer
7.4 Blood Cancer
7.5 Endocrine Cancer
7.6 Skin Cancer
7.7 Others
Chapter 8 Market Segmentation by Targeted Cancer Therapeutics
8.1 Hormone Therapy
8.2 Targeted Cancer Therapeutics
8.3 Signal Transduction Inhibitors
8.4 Immunotherapies
8.4.1 Monoclonal Antibodies
8.4.1.1 Naked Monoclonal Antibodies
8.4.1.2 Conjugated Monoclonal Antibodies
8.4.1.2.1 Radiolabeled Antibodies
8.4.1.2.2 Chemolabeled Antibodies
8.5 Cancer Vaccines
8.6 Non-Specific Immunotherapies
8.7 Others
Chapter 9 Market Segmentation by Application
9.1 Nasal Spray
9.2 Pills or Tablets
9.3 Skin Gel
9.4 Skin Patches
9.5 Vaginal Ring
9.6 Others
Chapter 10 Market Segmentation by Geography
10.1 North America
10.1.1 Introduction
10.1.2 United States
10.1.3 Canada
10.1.4 Mexico
10.1.5 Others
Chapter 11 Competitive Landscape
11.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
11.2 Market Share Analysis
11.3 Strategies Adopted By Top Companies
Chapter 12 Company Profiles
12.1 Genentech Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Benchmarking
12.1.4. Strategic Initiative
12.2 GlaxoSmithKline Plc
12.3 AstraZeneca Plc
12.4 Chugai Pharmaceutical Co., Ltd.
12.5 GPC Biotech Ag
12.6 Novartis
12.7 OSI Pharmaceuticals, Inc.
12.8 Pfizer
12.9 Abbott laboratories
12.10 Sanofi
12.11 Aveo pharmaceuticals
12.12 Hospira Inc.,
12.13 Bayer
12.14 Boehringer Ingelheim GmbH
Chapter 13 Market Estimates and Forecasting
13.1 Market Estimates and Forecasting 2018-2024(USD Million)
13.1.1 Market Estimation and Forecasting by Treatment Type 2018-2024 (USD Million)
13.1.2 Market Estimates and Forecasting by Cancer Type 2018-2024 (USD Million)
13.1.3 Market Estimates and Forecasting for Targeted Cancer Therapeutics 2018-2024 (USD Million)
13.1.4 Market Estimates and Forecasting by Application 2018-2024 (USD Million)
13.1.5 Market Estimates and Forecasting by Geography 2018-2024 (USD Million)
Chapter 14 Market Insights
14.1 Insights of Industry Experts
14.2 Analyst Opinion (Market Understanding)
14.3 Investment Opportunities
Chapter 15 Appendix
15.1 List of Tables
15.2 List of Figures
